Answers are grounded in this paper and cite their sources.
Glucopyranosyl lipid adjuvant (GLA) is a potent TLR4 agonist, but access to GLA adjuvants is constrained by complex chemical synthesis. We aimed to establish a biosynthesis-assisted route that combines microbial lipid A pathway engineering with a downstream chemical release step, using naturally derived MPLA as a reference. To minimize structural heterogeneity and direct secondary acylation toward C14, we engineered Escherichia coli by deleting six diversification genes and replacing native lpxL with vplpxL. The resulting C14-enriched LPS precursor was processed using a single mild acid-hydrolysis step, bypassing the conventional alkaline deacylation required for clinical-grade S. minnesota R595-derived MPLA. The purified product, GLA-Cx, was structurally characterized by high-resolution MS/MS and evaluated using complementary structural and impurity-related quality-control readouts (TLC, rFC, and hTLR2); it demonstrated in vitro murine and human TLR4 agonist activity. This process enabled repeatable recovery of 2.0–5.0 g per 35-L batch (57–143 mg L⁻¹), with combined penta- and hexa-acylated fractions of 43.92%–78.06% (61.30 ± 14.69%, mean ± SD, n = 5) of the grouped tetra- to hexa-acylated CAD area, compared with 26.97% for MPLA-SM. We establish an integrated genotype-to-product proof of concept for preparing C14-enriched monophosphorylated lipid A homologs from an engineered microbial cell factory. By combining W3110’s genetic tractability and hexa-acylated lipid A background with C14-directed design, single-step acid release without subsequent alkaline deacylation, and multi-gram recovery, this framework provides a basis for scalable production and quality-control development of complex lipid-based adjuvants.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: